EMA gives green light for meds previously manufactured at Ben Venue News item 12 January 2013 Pages: 1 - 1
CardioGen-82 is to return to the US market, with revised labelling to include a Boxed Warning, News item 12 January 2013 Pages: 2 - 2
EMA’s aliskiren review: new warnings and contraindications Media release 12 January 2013 Pages: 2 - 2
A letter clarifying the way the strength of Halaven (eribulin) is expressed in the product information News item 12 January 2013 Pages: 3 - 3
The EMA’s CHMP has recommended changes to the manufacturing process for Vivaglobin News item 12 January 2013 Pages: 3 - 3
Women with HIV infections (or at high risk for HIV) can still safely use hormonal contraceptives Media release 12 January 2013 Pages: 3 - 3
TGA updates on regulatory status of dextropropoxyphene products News item 12 January 2013 Pages: 3 - 3
The EMA is advising of an interaction between boceprevir and ritonavir-boosted HIV protease Media release 12 January 2013 Pages: 3 - 3
The risk of serious allergic reactions resulting from the use of blue dyes* for imaging purposes News item 12 January 2013 Pages: 4 - 4
Healthcare professionals and patients are warned by the US FDA about a counterfeit version of Avastin News item 12 January 2013 Pages: 4 - 4
Teva’s UK licence for manufacturing levothyroxine sodium 100µg tablets has been suspended Media release 12 January 2013 Pages: 4 - 4
